|
|
Post by awesomo on Jul 27, 2018 9:08:14 GMT -5
At least it is better than the RLS website which is a picture of a big tree. I'd prefer a picture of a tree, this Banks Bourne guy looks like the stereotypical dudebro ibanker that I went to business school with. |
|
|
|
Post by kenken on Jul 27, 2018 9:10:34 GMT -5
Is it an exclusive distribution or right to distribution only?
|
|
|
|
Post by peppy on Jul 27, 2018 9:13:50 GMT -5
It is legal to export any drug that has been FDA approved (and illegal if it has not). Companies like Tanner fill orders for customers in the numerous countries where virtually any FDA/EMA approved drug can be imported without further registration. It is a niche business but there is frequently demand for product in a foreign country, typically from just a few physicians who are familiar with the drug, often from being trained in the US. The good news is that Afrezza is now available to patients in many new countries, but the bad news is that most of those countries have tiny markets with low pricing relative to international standards. Most of the really attractive commercial markets are in Europe and those require will require an EMA approval. if you can pay, you get to play? alrighty. then. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 27, 2018 9:13:57 GMT -5
It is legal to export any drug that has been FDA approved (and illegal if it has not). Companies like Tanner fill orders for customers in the numerous countries where virtually any FDA/EMA approved drug can be imported without further registration. It is a niche business but there is frequently demand for product in a foreign country, typically from just a few physicians who are familiar with the drug, often from being trained in the US. The good news is that Afrezza is now available to patients in many new countries, but the bad news is that most of those countries have tiny markets with low pricing relative to international standards. Most of the really attractive commercial markets are in Europe and those require will require an EMA approval. Don't you think this deal signals a bit of desperation? Given the demands on Mike and his executive team, to devote valuable time to a deal such as this does not seem prudent? As far as driving sales in the United Stated, the recent ADA data is the only ammo Mike has. Your thoughts on if it will move the needle faster than what has been achieved in the past 12 months? |
|
|
|
Post by peppy on Jul 27, 2018 9:16:06 GMT -5
It is legal to export any drug that has been FDA approved (and illegal if it has not). Companies like Tanner fill orders for customers in the numerous countries where virtually any FDA/EMA approved drug can be imported without further registration. It is a niche business but there is frequently demand for product in a foreign country, typically from just a few physicians who are familiar with the drug, often from being trained in the US. The good news is that Afrezza is now available to patients in many new countries, but the bad news is that most of those countries have tiny markets with low pricing relative to international standards. Most of the really attractive commercial markets are in Europe and those require will require an EMA approval. Given the demands on Mike and his executive team, to devote valuable time to a deal such as this does not seem prudent? As far as driving sales in the United Stated, the recent ADA data is the only ammo Mike has. Your thoughts on if it will move the needle faster than what has been achieved in the past 12 months? quote: Don't you think this deal signals a bit of desperation? reply: no. pay to play is fine with me. we need 10,000 scripts a week. |
|
|
|
Post by awesomo on Jul 27, 2018 9:17:32 GMT -5
Don't you think this deal signals a bit of desperation? Given the demands on Mike and his executive team, to devote valuable time to a deal such as this does not seem prudent? As far as driving sales in the United Stated, the recent ADA data is the only ammo Mike has. Your thoughts on if it will move the needle faster than what has been achieved in the past 12 months? quote: Don't you think this deal signals a bit of desperation? reply: no. pay to play is fine with me. we need 10,000 scripts a week. Except these guys shipped 6,500 items for all their products in ONE YEAR. Tanner is not the answer. |
|
|
|
Post by mango on Jul 27, 2018 9:18:28 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 27, 2018 9:19:34 GMT -5
Don't you think this deal signals a bit of desperation? Given the demands on Mike and his executive team, to devote valuable time to a deal such as this does not seem prudent? As far as driving sales in the United Stated, the recent ADA data is the only ammo Mike has. Your thoughts on if it will move the needle faster than what has been achieved in the past 12 months? quote: Don't you think this deal signals a bit of desperation? reply: no. pay to play is fine with me. we need 10,000 scripts a week. I hope your joking. The PR is seriously anemic. You think some two bit schlock house is going to make a significant contribution. Likely a give it away initiative to try to reduce losses and if thats the strategy, we R fuct. |
|
|
|
Post by straightly on Jul 27, 2018 9:24:28 GMT -5
So they partnered with an I-banking guy who happened to start a small pharma group that hasn't updated their About Us stats in 4 years? Great... Has to be Amazon. It is wading into Pharma, and a lot of their operations have Bourne-Identity. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 27, 2018 9:29:54 GMT -5
So they partnered with an I-banking guy who happened to start a small pharma group that hasn't updated their About Us stats in 4 years? Great... Has to be Amazon. It is wading into Pharma, and a lot of their operations have Bourne-Identity. Anything to prove you claim? |
|
|
|
Post by mango on Jul 27, 2018 9:31:18 GMT -5
I sent Tanner an email for addiional details on their program for Afrezza, and for clarity concerning the 2014 distribution & customer satisfaction information on their website. Always a good idea to just ask instead of assume. 😎
|
|
|
|
Post by peppy on Jul 27, 2018 9:31:46 GMT -5
Has to be Amazon. It is wading into Pharma, and a lot of their operations have Bourne-Identity. Anything to prove you claim? That would be a dream come true. so good one. the minute share price jumps to 10 dollars I will believe. |
|
|
|
Post by straightly on Jul 27, 2018 9:33:49 GMT -5
investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-tanner-pharma-group-enter-ex-us-distributionMannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza® WESTLAKE VILLAGE, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation(Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a distribution agreement for Afrezza® with Tanner Pharma Group, a global provider of integrated specialty access solutions. The agreement names Tanner as a distributor of Afrezza® outside of the United States in regions the product is not yet registered. Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. “Al Mann had a vision of making Afrezza available to all people living with diabetes around the world and this agreement helps accelerate that access to Afrezza on a named patient access basis in underserved international markets,” said Michael Castagna, Chief Executive Officer of MannKind. “Our partnership with Tanner Pharma to distribute Afrezza provides us a strong partner with a track record of success in working with physicians, hospitals and ministries of health to provide medicine that is not currently available in their country.” The distribution will be managed by TannerGAP, Inc. (“TannerGAP”), a wholly owned subsidiary of Tanner Pharma Group. “We are pleased to partner with MannKind in helping fulfill the demand for Afrezza in countries outside the U.S.,” said Banks Bourne, Chairman and Founder of Tanner Pharma Group. To obtain additional details about the Tanner program for Afrezza, please call +1 704 552 8408 or email mannkind@tannerpharma.com. About Afrezza® Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit www.afrezza.com. About MannKind Corporation MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com. About Tanner Pharma Group For over 15 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners. Companies partner with Tanner Pharma to license and commercialize their products in challenging international markets, develop and manage their Global Access Programs, and source comparator drugs for clinical trials and bioanalysis. For more information, visit www.tannerpharma.com. Company Contact: Rose Alinaya SVP, Investor Relations 818-661-5000 ir@mannkindcorp.com Primary Logo Source: MannKind The terms and details of the agreement was not disclosed. Wait...did they not even say that? |
|
|
|
Post by casualinvestor on Jul 27, 2018 9:33:57 GMT -5
It is legal to export any drug that has been FDA approved (and illegal if it has not). Companies like Tanner fill orders for customers in the numerous countries where virtually any FDA/EMA approved drug can be imported without further registration. It is a niche business but there is frequently demand for product in a foreign country, typically from just a few physicians who are familiar with the drug, often from being trained in the US. The good news is that Afrezza is now available to patients in many new countries, but the bad news is that most of those countries have tiny markets with low pricing relative to international standards. Most of the really attractive commercial markets are in Europe and those require will require an EMA approval. Don't you think this deal signals a bit of desperation? Given the demands on Mike and his executive team, to devote valuable time to a deal such as this does not seem prudent? As far as driving sales in the United Stated, the recent ADA data is the only ammo Mike has. Your thoughts on if it will move the needle faster than what has been achieved in the past 12 months? I'm more thinking that the # of posts from you and awesomo regarding this minor good news signals a lot |
|
|
|
Post by boca1girl on Jul 27, 2018 9:34:12 GMT -5
quote: Don't you think this deal signals a bit of desperation? reply: no. pay to play is fine with me. we need 10,000 scripts a week. Except these guys shipped 6,500 items for all their products in ONE YEAR. Tanner is not the answer. I don’t believe “items” equates to “quantity”. They probably shipped 6,500 different items or products or sku’s. |
|
